top of page
News, Events and Updates
Search
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
15 minutes ago
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
2 days ago
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
Apr 5
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
Mar 31
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
Feb 24
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
Feb 12
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
Feb 5
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Jan 27
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
Jan 15
1
2
3
4
5
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
